赛伦生物(688163) - 2023 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2023 was ¥72,374,219.80, representing a year-on-year increase of 1.61%[5] - The net profit attributable to shareholders for Q3 2023 was ¥23,888,496.42, a decrease of 26.06% compared to the same period last year[5] - The net profit after deducting non-recurring gains and losses for Q3 2023 was ¥20,060,071.43, down 25.97% year-on-year[6] - The net profit for Q3 2023 was CNY 50,797,820.53, a decrease of 19.1% compared to CNY 62,771,140.81 in Q3 2022[21] - Total revenue for the first three quarters of 2023 reached ¥166,133,808.11, an increase of 11.3% compared to ¥149,434,599.86 in the same period of 2022[30] - Net profit for the first three quarters of 2023 was ¥52,373,135.70, a decrease of 17.0% compared to ¥63,106,277.36 in the same period of 2022[31] Research and Development - The total R&D investment for Q3 2023 was ¥13,108,615.11, an increase of 249.91% compared to the same period last year[6] - R&D investment accounted for 18.11% of operating revenue in Q3 2023, up 12.85 percentage points year-on-year[6] - The company is focusing on the development of new products, including antivenom serums and rapid diagnostic reagents, which have seen increased R&D investment[10] - Research and development expenses increased significantly to CNY 22,111,264.41, up from CNY 9,537,393.92, representing a growth of 132.5% year-over-year[20] - Research and development expenses increased significantly to ¥22,459,586.29, up 132.5% from ¥9,675,989.56 in the first three quarters of 2022[30] Cash Flow and Liquidity - The net cash flow from operating activities for the year-to-date period decreased by 70.16% to ¥18,739,814.65[9] - The cash flow from operating activities for the first nine months of 2023 was CNY 18,739,814.65, a decrease from CNY 62,795,469.40 in the same period last year[24] - The company reported a net cash outflow from investing activities of CNY -331,567,873.09 for Q3 2023, compared to CNY -753,906,332.87 in Q3 2022[24] - Cash and cash equivalents decreased to RMB 121,998,400.36 from RMB 515,730,469.86 at the end of 2022, showing a decline of approximately 76.4%[15] - The ending cash and cash equivalents balance was ¥121,896,594.12, up from ¥110,970,437.54, reflecting an increase of 9.0%[34] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,129,138,906.13, a decrease of 2.92% from the end of the previous year[6] - As of September 30, 2023, total current assets amounted to RMB 956,456,829.05, a decrease from RMB 997,054,745.62 at the end of 2022, reflecting a decline of about 4.9%[15] - The company's total assets as of September 30, 2023, were RMB 1,129,138,906.13, down from RMB 1,163,066,774.97 at the end of 2022, a decrease of about 2.9%[17] - Non-current liabilities totaled RMB 17,672,174.07 as of September 30, 2023, compared to RMB 14,904,469.77 at the end of 2022, indicating an increase of approximately 18.5%[17] - The company's total liabilities decreased to RMB 37,874,811.76 from RMB 41,776,323.39 at the end of 2022, reflecting a reduction of about 9.4%[17] Earnings and Shareholder Equity - The weighted average return on equity for Q3 2023 was 2.21%, a decrease of 0.72 percentage points year-on-year[6] - The basic earnings per share for Q3 2023 was ¥0.22, down 29.03% compared to the same period last year[6] - Basic and diluted earnings per share for Q3 2023 were both CNY 0.47, down from CNY 0.63 in Q3 2022[21] - The company's retained earnings as of September 30, 2023, were RMB 69,947,592.08, down from RMB 99,973,949.29 at the end of 2022, indicating a decline of approximately 30.1%[17] - The total equity attributable to shareholders decreased to RMB 1,091,264,094.37 from RMB 1,121,290,451.58 at the end of 2022, a decrease of about 2.7%[17]